In vitro and in vivo anti-malarial activity of Boerhavia elegans and Solanum surattense by Ali Ramazani et al.
Ramazani et al. Malaria Journal 2010, 9:124
http://www.malariajournal.com/content/9/1/124
Open AccessR E S E A R C HResearchIn vitro and in vivo anti-malarial activity of 
Boerhavia elegans and Solanum surattense
Ali Ramazani1, Sedigheh Zakeri*1, Soroush Sardari2, Nastaran Khodakarim1 and Navid Dinparas Djadidt1
Abstract
Background: There is an urgent need to identify new anti-malarial drug targets for both prophylaxis and 
chemotherapy, due to the increasing problem of drug resistance to malaria parasites. In the present study, the aim was 
to discover novel, effective plant-based extracts for the activity against malaria.
Methods: Ten plants found in Iran were selected by ethnobotanical survey of medicinal plants. The crude ethanolic 
extracts were tested for in vitro anti-plasmodial activity against two strains of Plasmodium falciparum: K1 (chloroquine-
resistant strain) and CY27 (chloroquine-sensitive strain), using the parasite lactate dehydrogenase (pLDH) assay. The 
anti-plasmodial activity of the extracts was also assessed in the 4-day suppressive anti-malarial assay in mice inoculated 
with Plasmodium berghei (ANKA strain). Crude ethanolic extracts showed good anti-plasmodial activity were further 
fractionated by partitioning in water and dichloromethane.
Results: Of 10 plant species assayed, three species: Boerhavia elegans (Choisy), Solanum surattense (Burm.f.) and Prosopis 
juliflora (Sw.) showed promising anti-plasmodial activity in vitro (IC50 ≤ 50 μg/ml) and in vivo with no toxicity. The 
dichloromethane fraction of three extracts revealed stronger anti-plasmodial activity than the total extracts.
Conclusion: Anti-plasmodial activities of extracts of B. elegans and S. surattense are reported for the first time.
Background
Malaria is one of the oldest recorded diseases in the
world. Each year 300 to 500 million new cases are diag-
nosed and approximately 1.5 million people die of the
disease; the majority of them are children [1]. The re-
emerging of malaria in many parts of the world is due to
the rapid increase of resistance to most of the available
anti-malarial drugs, as well as resistance of vectors to
insecticides [2,3]. Drug resistant strains of P. falciparum
have been found in many endemic areas of the world and
many of conventional anti-malarial drugs have been asso-
ciated with treatment failure. Furthermore, the difficulty
of creating efficient vaccines and also adverse side-effects
of the existing anti-malarial drugs highlight the urgent
need for novel, well-tolerated anti-malarial drugs [2] for
both prophylaxis and treatment of malaria.
History reveals that plants have always been considered
as an important source of medicine against malaria: both
quinine and artemisinin have been derived from tradi-
tional medicine and plant extracts. Artemisinin deriva-
tives are now recommended by the World Health
Organization worldwide [4,5], in combination with other
drugs, such as lumefantrine, amodiaquine, mefloquine,
sulphadoxine-pyrimethamine (SP), as the first-line treat-
ment of malaria. This fact has encouraged the continuing
search for new natural product-derived anti-malarial
drugs. In malaria-endemic countries, several plants are
utilized in traditional medicine for the treatment of
malaria and/or fever. Furthermore, several studies have
been undertaken to evaluate not only the inhibitory
effects of various plant extracts on P. falciparum [6,7]
using in vitro culture, but also in vivo anti-malarial prop-
erties on Plasmodium berghei-infected mice [8,9].
Malaria is endemic in Iran with 16,000 cases in 2008
(Center for Diseases Management and Control, Ministry
of Health and Medical Education, unpublished). Despite
intensive efforts to control malaria, the disease continues
to be one of the greatest health problems in the south-
eastern part of the country. In Iran, P. falciparum resis-
tance to CQ has been reported since 1983 [10]. As the
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Page 2 of 8intensity of CQ resistance increased, the country imple-
mented a change of first-line anti-malarial treatment in
2007 to a combination of SP-artesunate with artemether-
lumefantrine (Coartem®), as the second-line drug [11].
Considering the great potential of Iranian plant biodiver-
sity and based on ancient Iranian traditional physician's
books [12-15], 10 different species of Iranian medicinal
plants were selected in this investigation. The aim of this
study was to discover novel, effective plant-based medi-
cines for the treatment of malaria. In light of this, in vitro
screening the anti-plasmodial properties of these plant
species and their possible cytotoxic activities were also
determined using the brine shrimp assay [16]. Subse-
quently, based on in vitro results, the active extracts were
followed-up in a murine model of malaria.
Methods
Selection and collection of plant materials
Based on literature and interviews with traditional health
practitioners, plants representing five families, seven gen-
era, and 10 species that used against fever, inflammation
and microbial infection have been selected. The plants
were collected from different parts of Iran, Sistan and
Baluchistan, Khouzestan and Fars provinces, from March
2005 to October 2007 (Figure 1). Collections were under-
taken from areas endemic for malaria at the present (Sis-
tan and Baluchistan) and that had been endemic in the
past (Khouzestan and Fars).
The specimens were identified by Dr. S. Sardari and
voucher specimens were deposited at Drug Discovery
Group of Biotechnology Research Center at Institut Pas-
teur of Iran (Table 1). After identification, aerial parts of
each specimen were air-dried in shadow at room temper-
ature. The plants were crushed into fine powder using an
electric grinder. The powdered samples were stored in
appropriate containers and were kept at a cold room
(4°C). The studied plant species were indicated in Table 1.
Extraction and fractionation
For each plant, 100 g of powdered materials was
extracted by percolation three times using 80% ethanol at
room temperature. The ethanol extracts were filtered,
pooled and dried at 40°C or below using a rotary evapora-
tor. All the extracts were kept in airtight containers and
were stored at 4°C for use in anti-plasmodial bioassay and
general toxicity tests. Crude ethanolic extracts that
showed good anti-plasmodial activity against P. falci-
parum strains, were further fractionated by partitioning
in water and dichloromethane. The organic and aqueous
phases were concentrated and dried by rotary evaporator
and were dissolved in dimethylsulphoxide (DMSO) and
Figure 1 Map of Iran showing plant collecting places: Sistan and Baluchistan, Khouzestan and Fars Provinces.
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20°C for use in anti-plasmodial assay.
Plasmodium falciparum strains and in vitro culture
Laboratory-adapted P. falciparum K1 (chloroquine-resis-
tant) and CY27 (chloroquine-sensitive) strains, both orig-
inally obtained from Thai patients, were continuously
cultured based on a modified method previously
described [17]. Briefly, parasites were maintained in con-
tinuous culture on human erythrocytes (blood group O+
obtained from the Blood Transfusion Organization, Teh-
ran, Iran), in RPMI 1640 medium supplemented with 10%
human AB+ serum, 25 mM N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid (HEPES), 25 mM NaHCO3, and
60 μg/ml gentamicin sulfate, at pH 7.2. The cultures were
incubated at 37°C in an atmosphere of 91% N2, 6% CO2
and 3% O2. Parasite cultures were synchronized to the
ring stage by treatment with 5% D-sorbitol [18].
In vitro anti-plasmodial assay
Plant extracts were assessed for anti-plasmodial activity
in vitro using modified parasite lactate dehdrogenase
(pLDH) method as described previously [19,20]. Crude
plant extracts were first dissolved in DMSO at concentra-
tion of 50 mg/ml, sonicated for 10 min and then diluted
in malaria culture medium to prepare a 2 mg/ml solution.
The highest concentration of solvent that the parasites
were exposed to was < 1%, which was shown to have no
measurable effect on parasite viability. Microtitration
techniques were used to measure the activity of samples
over a wide range of concentrations (ranging from 200-
1.56 μg/ml). Chloroquine diphosphate and artemisinin
(both from Sigma Chemical, USA) were dissolved in dou-
ble distilled water (1 mg/ml) and DMSO (1 mg/ml),
respectively and served as controls in all experiments. All
tests were performed in triplicate. Synchronous cultures
with parasitaemia of 1% and a final haematocrit of 1.5%
were aliquoted into the plates and incubated at 37°C for
72 h. After incubation period, the plates were frozen at -
20°C overnight, followed by thawing at room temperature
to haemolyze the red blood cells. Parasite growth was
determined spectrophotometrically at 650 nm, by mea-
suring the activity of the pLDH in control and drug-
treated cultures, using a microplate reader (PowerWave
340, BioTek, USA). At the end of incubation, the cultures
were resuspended, and aliquots of 20 μl were removed
and added to 100 μl of the Malstat reagent [19,20] in a 96-
well microtiter plate. The spectrophotometric assessment
of pLDH activity was obtained by adding 25 μl of a solu-
tion of 1.9 μM NBT (Nitro Blue Tetrazolium) and 0.24
μM PES (Phenazine Ethosulphate) to the Malstat reagent.
The anti-malarial activity of the test compound was
expressed as IC50 (mean ± S.D. of the least three separate
experiments performed in triplicate). The OD values
from control wells devoid of plant extracts or drug were
referred to as having 100% pLDH activity. The inhibition
Table 1: Names and origins of the selected plants of Iran




Some traditional uses (Jorjani, 












S & B March, 2005 Antipyretic, inflammation CH-45
Solanaceae Solanum alatum Khouzestan October, 2007 Headache, infection, wound 
healing, dysentery
74-10
Fabaceae Prosopis juliflora Khouzestan October, 2007 Fever, inflammation 74-32
Moraceae Ficus bengalensis Khouzestan May, 2007 Wound healing, sedative, anti-
rheumatism, inflammation
74-31
Moraceae Ficus carica Khouzestan May, 2007 Ascites, a Anemia, inflamation 74-46
Rutaceae Citrus limon Khouzestan May, 2007 disinfectant, rheumatism, 
inflammation
74-35
Moraceae Morus alba Khouzestan May, 2007 Antipyretic, diuretic, laxative 74-38
Fabaceae Acacia farnesiana Khouzestan May, 2007 wound healing, analgesic 74-37
Rutaceae Citrus aurantifolia 
Swingle
Fars September, 2007 Disinfectant, sedative, cold, 
appetite,
78-3
S & B = Sistan and Baluchistan
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compared to the untreated control to obtain the IC50 val-
ues. These values were then expressed as a percentage of
100% growth value and plotted against corresponding
concentrations of the drug, using Gene5 micrroplate data
collection and analysis software (BioTek, USA) to gener-
ate log dose-response curves.
Brine shrimp toxicity assay
Inhibition of the growth of brine shrimps (Artemia
salina) was used as a measure of the toxicity of the
extracts. The general toxicity in brine shrimp lethality
test was carried out according to the methodology
described before [16] by using brine shrimp eggs,
obtained from Artemia and Aquatic Animals Research
Center (Urmia University, Urmia, Iran). The eggs were
hatched in artificial sea water (38 g/lit saline) in a vessel
described previously [21]. After a 28-30 h hatching
period at room temperature, the nauplii were ready for
the experiment.
Extracts were prepared by dissolving 50 mg/ml in
DMSO and then serially diluted in artificial sea water to
the desired concentrations. The final DMSO concentra-
tion did not exceed 1%, which was shown not to have any
harmful effects on the larvae. Finally, ten shrimps in 100
μl of artificial sea water were added to each vial to give a
final volume of 2.5 ml. After 24 h, the survivors were
counted under microscope and recorded. Gallic acid
(LC50 = 20 μg/ml) was used as a positive control, and vials
containing shrimps, but without any extracts were
included in each test. The toxicity of each extract was
determined from the 50% lethality dose (LC50) by
Finney's Probit analysis [22] of the data created with SPSS
15.0 for windows (SPSS Inc., USA). The general toxicity
activity was considered weak when the LC50 was between
500 and 1000 μg/ml, moderate when the LC50 was
between 100 and 500 μg/ml, and strong when the LC50
ranged from ≤ 100 μg/ml [23].
In vivo anti-plasmodial assay
The anti-plasmodial activity of the Prosopis juliflora
(Sw.), Boerhavia elegans (Choisy), and Solanum surat-
tense (Burm.f.) extracts were assessed by the classical 4-
day suppressive test [24,25]. Female BALB/C mice,
weight 18-20 g were infected by interaperitoneal (i.p.)
inoculation of 107 infected erythrocytes with CQ-sensi-
tive P. berghei (ANKA strain) in a saline suspension of 0.2
ml on the first day (D0) of the experiment.
Plant extracts were solubilized in 18% DMSO or in PBS
(water-soluble extract) and administrated within 3 h
post-inoculation of mice with the parasite (D0) at differ-
ent concentrations in a dose volume of 0.2 ml. Groups of
five mice were dosed daily by i.p. injection for 4 consecu-
tive days. On day 4, tail blood smear were taken, stained
with 10% Giemsa in phosphate buffer, pH 7.2 for 15 min
and examined under microscope at 100 ×. The percent-
age parasitaemia was determined by counting the parasit-
ized red blood cells on at least 3,000 red blood cells. The
% suppression of parasitaemia was calculated for each
extract by comparing the parasitaemia present in infected
controls with those of test mice. Chloroquine diphos-
phate (25 mg/kg), PBS and DMSO (18%) were used as
positive and negative controls, respectively. For all the
groups survival time in days was recorded and the mean
for each group calculated. The results were analysed sta-
tistically using one-way ANOVA and two-tailed Student's
t-test (SPSS 15.0 Inc., USA) to identify the differences
between treated group and controls. The data were con-
sidered significant at P < 0.05.
Results
In vitro anti-plasmodial assay
In vitro activity of 10 plant extracts against CQ-sensitive
(CY27) and -resistant (K1) P. falciparum strains are sum-
marized in Table 2. Of 10 extracts tested, three showed
significant anti-plasmodial activity at a concentration of
4.68 to 50 μg/ml. Three hydro-alcoholic extracts of Pr.
juliflora, B. elegans and S. surattense. showed significant
anti-plasmodial activity against both chloroquine-resis-
tant (K1) (IC50: 14.78, 15.33 and 50 μg/ml, respectively)
and chloroquine-sensitive (CY27) (IC50: 4.68, 11.97 and
40.88 μg/ml, respectively). The rest of the other plant
extracts showed weak or no activity (IC50 > 200 μg/ml)
against the studied isolates. The selectivity index (SI) is
defined as the ratio of the brine shrimp toxicity to the
anti-plasmodial activity and is determined by dividing the
LC50 values for the brine shrimp nauplii by the IC50 value
for P. falciparum. The extract with higher selectivity (high
SI value) indicate potentially safer therapy.
The crude extract of three active extracts (Pr. juliflora,
B. elegans and S. surattense) were further fractionated in
water and dichloromethane mixture solution and the
anti-plasmodial activity of organic and aqueous phases
was evaluated against CQ-resistant and -sensitive P. falci-
parum strains. The dichloromethane fraction of the three
extracts also showed stronger anti-plasmodial activity
than the total extracts (Table 3).
Brine shrimp toxicity test
All the ethanolic active extracts were screened against
brine shrimp nauplii and the results showed no signifi-
cant or toxicity activity (LC50 > 1,000 μg/ml) for Pr. juli-
flora, B. elegans, S. surattense, Solanum alatum and Ficus
bengalensis. However, the rest of the extracts showed
mild toxicity (LC50 100-500 μg/ml) (Table 2).
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Table 4 shows a summary of parasitaemia suppression
(%) for mice on day 4. Three extracts from three plant
species showed a significant suppression of parasitaemia
(P < 0.05) ranging from 44.1 to 66.2%. In contrast, results
with the water-soluble extracts of Pr. juliflora were non-
significant (P > 0.05) (Table 4). Based on day 10 post-
infection, S. surattense extract gave 80%, but Pr. juliflora.
and B. elegans gave 100% mouse survival.
Discussion
In this investigation, anti-plasmodial activity of 10 Ira-
nian traditional selected plants, representing five families
was studied. The anti-plasmodial activities of the extracts
were qualified as "active" when IC50 is ≤ 50 μg/ml.
Extracts having activity beyond this range were consid-
ered inactive. The selectivity index (SI) is defined as the
ratio of the cytotoxicity on the brine shrimp to the anti-
plasmodial activity. Those that showed high SI (>10)
should offer the potential for safer therapy.
Table 2: In vitro bioassays on P. falciparum CY27 and K1 strains and toxicity assay of the selected plants
Scientific name Artemia 
salina assay, 
LC50 (μg/ml)
Anti-plasmodial activity, IC50 
(μg/ml) ± SD
SI
No. Family Species K1 CY27 K1 CY27
1 Nyctaginaceae Boerhavia 
elegans
1020 15.33 ± 0.07 11.97 ± 0.05 18.19 23.3
2 Solanaceae Solanum 
surattense
2507 50 ± 0.09 40.88 ± 0.84 61.32 48.86
3 Solanaceae Solanum 
alatum
1050 >200 >200 NA NA
4 Fabaceae Prosopis 
juliflora
1636.68 14.78 ± 0.08 4.68 ± 0.03 110.73 349.71
5 Moraceae Ficus 
bengalensis
1050 >200 >200 NA NA
6 Moraceae Ficus carica 130.16 >200 >200 NA NA
7 Rutaceae Citrus limon 471.39 >200 >200 NA NA
8 Moraceae Morus alba 256.42 >200 >200 NA NA
9 Fabaceae Acacia 
farnesiana
460.12 >200 >200 NA NA
10 Rutaceae Citrus 
aurantifolia 
Swingle
270.17 >200 >200 NA NA
Gallic acid 20 ND ND NA NA
Controls Chloroquine ND 1.25 ± 0.08 0.4 ± 0.01 NA NA
Artemisinin ND 0.002 ± 0008 0.007 ± 0.0005 NA NA
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and S. surattense showed promising anti-plasmodial
activity with IC50 values of ≤ 50 μg/ml and SI ranging
between 18.19 and 349.71. From these three species, two
(Pr. juliflora and B. elegans) were found to be highly
active with IC50 values of < 20 μg/ml. The crude extract of
these three active herbs was further fractionated with a
mixture of water and dichloromethane. The dichlo-
romethane fraction of three active plants showed anti-
plasmodial activity, but only the aqueous phase of Pr. juli-
flora showed activity against two strains of P. falciparum.
Fortunately, these three active plants had low toxicity
indicating the possibility of using them as lead structures
in further studies.
Prosopis juliflora (IC50 = 14.78 μg/ml on K1 strain, SI =
110.73 and IC50 = 4.68 μg/ml on CY27 strain, SI = 349.71)
is a tree native to Mexico, South America and Caribbean
that later become established as a weed in Asia, Australia
and elsewhere (Figure 2A). Pr. juliflora has been used in
traditional medicine for fever, inflammation, scurvy, as a
disinfectant, healing of wounds and skin problems [26].
The anti-malarial activity of this plant against CQ-sus-
ceptible strain of P. falciparum (3D7) was previously
reported [27] and the present result correlates well with
that and our study confirmed this observation with
higher activity than previous study against both CQ-
resistant (K1) and -sensitive (CY27) strains. Furthermore,
treatment with the dichloromethane extract of Pr. juli-
flora significantly inhibited parasitaemia of P. berghei
infection in BALB/c mice compared to no treatment,
implying direct parasiticidal activity. The water-soluble
extract of Pr. juliflora was active in in vitro against both
sensitive and resistance P. falciparum strains, but had no
in vivo activity against P. berghei. The results for in vivo
anti-malarial activity do not necessarily correlate with
Table 3: Anti-plasmodial activity (IC50) of water-soluble and dichloromethane fractions of three active plants against P. 
falciparum strains
Plant species IC50 (μg/ml) ± *SD
K1 CY27
Aqueous Dichloromethane Aqueous Dichloromethane
B. elegans >200 15 ± 0.38 >200 9.37 ± 0.01
S. surattense >200 40 ± 0.16 >200 18.75 ± 0.4
Pr. juliflora 32.43 ± 0.2 9.95 ± 0.06 18 ± 0.16 1.4 ± 0.02
*SD = Standard deviation
Table 4: In vivo activities of plant extracts against P. berghei




day 4 (SP ± SD*)
Survival (%) on 
day 10
P value (P < 0.05)
S. surattense Dichloromethane 100 58.11 ± 4.3 80 0.035
Pr. juliflora Dichloromethane 100 44.13 ± 1.79 100 0.008
Water-soluble 
extract
50 2.59 ± 1.54 100 0.598
B. elegans Dichloromethane 300 66.18 ± 2.11 100 0.007
PBS - 0 100
DMSO 18% 0 100
CQ 25 100 100
* SD = Standard deviation
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[28] and this may be due to poor bioavailability of the
active compounds in vivo.
Boerhavia elegans is an erect herb up to 1 m high, with
a stout rootstock. The stems fleshy become woody
towards the base, which is green, often flushed with red,
glabrescent to pubescent, branching mainly from the base
with the nodes swollen. Its leaves broadly ovate to lanceo-
late, green above, grayish-white beneath, sometimes
tinged purple (Figure 2B). It showed promising anti-plas-
modial activity with an IC50 = 15.33 μg/ml on K1 strain
(SI = 18.19) and IC50 = 11.97 μg/ml on CY27 strain (SI =
23.3). The dichloromethane extract of B. elegans had the
highest suppressive activity on P. berghei (66.18%) at a
concentration of 300 mg/kg/per day. The result has
shown promising suppressive and curative anti-malarial
activities in P. berghei infected mice.
Solanum surattense is a suffrutescent perennial under-
shrub plant, which grows in dry situations throughout
India. The zigzag branches spread close to the ground
covered with strong, broad and sharp yellowish white
prickles. Its leaves armed with sharp prickles, blue flow-
ers, fruit berries, yellow or white (Figure 2C). This species
also showed anti-plasmodial activity with an IC50 = 50 μg/
ml on K1 strain (SI = 61.32) and IC50 = 40.88 μg/ml on
CY27 strain (SI = 48.86) and in vivo anti-plasmodial
activities with 58.11% suppression.
B. elegans and S. surattense are growing in the south-
eastern of Iran, where malaria is endemic. In Sistan and
Baluchistan province, people use the extract of S. surat-
tense against fever and infections. Also, this plant and B.
elegans are used for inflammation in folk medicine [29].
No biological properties have been reported in the litera-
ture for these species, and the anti-plasmodial activity of
these two plants is reported for the first time in the pres-
ent study. It is interesting to note that the majority of the
aqueous extracts did not show any activity. However, the
dichloromethane fraction of three extracts showed better
anti-plasmodial activity than the total extracts.
In this study, a number of selected plants did not dis-
play in vitro anti-plasmodial activity. Among them, Aca-
cia farnesiana was collected from Khouzestan province
in Iran and showed no anti-plasmodial activity. However,
an ethanolic extract of this plant from Colombia had
shown anti-plasmodial activity against P. falciparum [30].
A possible explanation could be that factors such as
chemotypes, environmental parameters, harvesting and
storage conditions that could collectively influence the
plant metabolites prior to and following harvestings,
which in turn, would be reflected in the bioactivity.
Conclusion
Overall, increasing the global spread of multi-drug resis-
tant malaria parasite showed that there is a need for new
chemotherapeutic agents to combat malaria. In this
study, aiming to search for new anti-malarial drugs, we
found, for the first time, in vitro and in vivo anti-plasmo-
dial activities of the plants B. elegans and S. surattense.
The plant Pr. juliflora has already been described in the
literature for anti-malarial activity against CQ-sensitive P.
falciparum strain and the present study also confirmed
these observations against CQ-resistant P. falciparum
strain as well as on P. berghei. The present finding is only
preliminary, the next step will be to isolate and identify
the active compound of both B. elegans and S. surattense.
Figure 2 Image of A: Prosopis juliflora called "Somr" in Khouz-
estan province. B: Boerhavia elegans, called "Sourkho" in Sistan and Ba-
luchistan province; C: Solanum surattense called "Tajrizi Baluchi" in 
Sistan and Baluchistan province, Iran. All these plants showed in vitro 
and in vivo anti-plasmodial activity.
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